Registro:

Referencias:

• Ferlay, J., Soerjomataram, I., Ervik, M., Cancer incidence and mortality worldwide: IARC CancerBase No.11 (2013) International Agency for Research on Cancer
• Denmeade, S.R., Isaacs, J.T., A history of prostate cancer treatment (2002) Nat Rev Cancer, 2, pp. 389-396
• Taniguchi, N., Nakamura, K., Narimatsu, H., von der Lieth, C.W., Paulson, J., Human disease glycomics/proteome initiative workshop and the 4th HUPO Annual Congress (2006) Proteomics, 6, pp. 12-13
• Lowe, J.B., Glycosylation, immunity, and autoimmunity (2001) Cell, 104, pp. 809-812
• Dube, D.H., Bertozzi, C.R., Glycans in cancer and inflammation potential for therapeutics and diagnostics (2005) Nat Rev Drug Discov, 4, pp. 477-488
• Liu, F.T., Rabinovich, G.A., Galectins as modulators of tumour progression (2005) Nat Rev Cancer, 5, pp. 29-41
• Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer (2012) Immunity, 36, pp. 322-325
• Elola, M.T., Wolfenstein-Todel, C., Troncoso, M.F., Vasta, G.R., Rabinovich, G.A., Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival (2007) Cell Mol Life Sci, 64, pp. 1679-1700
• Compagno, D., Jaworski, F.M., Gentilini, L., Contrufo, G., Gonzalez-Perez, I., Elola, M.T., Pregi, N., Laderach, D.J., Galectins: major signaling modulators inside and outside the cell (2014) Curr Mol Med, 14, pp. 630-651
• Laderach, D.J., Compagno, D., Toscano, M.A., Croci, D.O., Dergan-Dylon, S., Salatino, M., Rabinovich, G.A., Dissecting the signal transduction pathways triggered by galectinglycan interactions in physiological and pathological settings (2011) IUBMB Life, 62, pp. 1-13
• Laderach, D.J., Gentilini, L.D., Giribaldi, L., Delgado, V.C., Nugnes, L., Croci, D.O., Al Nakouzi, N., Chauchereau, A., A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease (2013) Cancer Res, 73, pp. 86-96
• Su, Z.Z., Lin, J., Shen, R., Fisher, P.E., Goldstein, N.I., Fisher, P.B., Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family (1996) Proc Natl Acad Sci U S A, 93, pp. 7252-7257
• Levy, Y., Arbel-Goren, R., Hadari, Y.R., Eshhar, S., Ronen, D., Elhanany, E., Geiger, B., Zick, Y., Galectin-8 functions as a matricellular modulator of cell adhesion (2001) J Biol Chem, 276, pp. 31285-31295
• Zick, Y., Eisenstein, M., Goren, R.A., Hadari, Y.R., Levy, Y., Ronen, D., Role of galectin-8 as a modulator of cell adhesion and cell growth (2004) Glycoconj J, 19, pp. 517-526
• Arbel-Goren, R., Levy, Y., Ronen, D., Zick, Y., Cyclindependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8 (2005) J Biol Chem, 280, pp. 19105-19114
• Troncoso, M.F., Elola, M.T., Croci, D.O., Rabinovich, G.A., Integrating structure and function of 'tandem-repeat' galectins (2012) Front Biosci (Schol Ed), 4, pp. 864-887
• Zappelli, C., van der Zwaan, C., Thijssen-Timmer, D.C., Mertens, K., Meijer, A.B., Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes (2012) J Biol Chem, 287, pp. 8327-8335
• Schumacher, D., Strilic, B., Sivaraj, K.K., Wettschureck, N., Offermanns, S., Platelet-derived nucleotides promote tumorcell transendothelial migration and metastasis via P2Y2 receptor (2013) Cancer Cell, 24, pp. 130-137
• Bidon-Wagner, N., Le Pennec, J.P., Human galectin-8 isoforms and cancer (2004) Glycoconj J, 19, pp. 557-563
• Chauchereau, A., Al Nakouzi, N., Gaudin, C., Le Moulec, S., Compagno, D., Auger, N., Benard, J., Fizazi, K., Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer (2011) Exp Cell Res, 317, pp. 262-275
• Al Nakouzi, N., Bawa, O., Le Pape, A., Lerondel, S., Gaudin, C., Opolon, P., Gonin, P., Chauchereau, A., The IGRCaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer (2012) Neoplasia, 14, pp. 376-387
• Chauchereau, A., Experimental models for the development of new medical treatments in prostate cancer (2011) Eur J Cancer, 47, pp. S200-S214
• Gumbiner, B.M., Cell adhesion: the molecular basis of tissue architecture and morphogenesis (1996) Cell, 84, pp. 345-357
• van den Brule, F., Califice, S., Garnier, F., Fernandez, P.L., Berchuck, A., Castronovo, V., Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin (2003) Lab Invest, 83, pp. 377-386
• Califice, S., Castronovo, V., Van Den Brule, F., Galectin-3 and cancer (Review) (2004) Int J Oncol, 25, pp. 983-992
• Compagno, D., Gentilini, L.D., Jaworski, F.M., Perez, I.G., Contrufo, G., Laderach, D.J., Glycans and galectins in prostate cancer biology, angiogenesis and metastasis (2014) Glycobiology, 24, pp. 899-906
• Pienta, K.J., Naik, H., Akhtar, A., Yamazaki, K., Replogle, T.S., Lehr, J., Donat, T.L., Raz, A., Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin (1995) J Natl Cancer Inst, 87, pp. 348-353
• Clausse, N., van den Brule, F., Waltregny, D., Garnier, F., Castronovo, V., Galectin-1 expression in prostate tumorassociated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion (1999) Angiogenesis, 3, pp. 317-325
• Glinskii, O.V., Sud, S., Mossine, V.V., Mawhinney, T.P., Anthony, D.C., Glinsky, G.V., Pienta, K.J., Glinsky, V.V., Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine (2012) Neoplasia, 14, pp. 65-73
• Ahmed, H., Banerjee, P.P., Vasta, G.R., Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation (2007) Biochem Biophys Res Commun, 358, pp. 241-246
• Wang, Y., Nangia-Makker, P., Tait, L., Balan, V., Hogan, V., Pienta, K.J., Raz, A., Regulation of prostate cancer progression by galectin-3 (2009) Am J Pathol, 174, pp. 1515-1523
• Tsai, C.H., Tzeng, S.F., Chao, T.K., Tsai, C.Y., Yang, Y.C., Lee, M.T., Hwang, J.J., Hsiao, P.W., Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells (2016) Cancer Res, 76, pp. 5756-5767
• Levy, Y., Ronen, D., Bershadsky, A.D., Zick, Y., Sustained induction of ERK, protein kinase B, and p70 S6 kinase regulates cell spreading and formation of F-actin microspikes upon ligation of integrins by galectin-8, a mammalian lectin (2003) J Biol Chem, 278, pp. 14533-14542
• Kim, H.R., Lin, H.M., Biliran, H., Raz, A., Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells (1999) Cancer Res, 59, pp. 4148-4154
• Sanchez-Ruderisch, H., Detjen, K.M., Welzel, M., Andre, S., Fischer, C., Gabius, H.J., Rosewicz, S., Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor alpha5beta1-integrin (2011) Cell Death Differ, 18, pp. 806-816
• Sanchez-Ruderisch, H., Fischer, C., Detjen, K.M., Welzel, M., Wimmel, A., Manning, J.C., Andre, S., Gabius, H.J., Tumor suppressor p16 INK4a: downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model (2010) FEBS J, 277, pp. 3552-3563
• Nakahara, S., Oka, N., Raz, A., On the role of galectin-3 in cancer apoptosis (2005) Apoptosis, 10, pp. 267-275
• Bacigalupo, M.L., Manzi, M., Espelt, M.V., Gentilini, L.D., Compagno, D., Laderach, D.J., Wolfenstein-Todel, C., Troncoso, M.F., Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells (2015) J Cell Physiol, 230, pp. 1298-1309
• Compagno, D., Merle, C., Morin, A., Gilbert, C., Mathieu, J., Bozec, A., Mauduit, C., Cabon, F., siRNAdirected in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas (2007) PLoS One, 2

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------